Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Liabilities and Shareholders Equity (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $36.6 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 101.44% to $36.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $123.2 million through Dec 2025, up 5.69% year-over-year, with the annual reading at $28.6 million for FY2025, N/A changed from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $36.6 million at Neuphoria Therapeutics, up from $27.3 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $46.8 million in Q2 2022, with the low at $18.2 million in Q4 2024.
  • Average Liabilities and Shareholders Equity over 4 years is $30.0 million, with a median of $28.7 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity crashed 38.56% in 2023, then soared 101.44% in 2025.
  • Over 4 years, Liabilities and Shareholders Equity stood at $46.8 million in 2022, then plummeted by 38.56% to $28.7 million in 2023, then crashed by 36.79% to $18.2 million in 2024, then surged by 101.44% to $36.6 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $36.6 million, $27.3 million, and $28.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.